This company has been acquired
Aerie Pharmaceuticals Management
Management criteria checks 2/4
Key information
Raj Kannan
Chief executive officer
US$4.3m
Total compensation
| CEO salary percentage | 0.6% |
| CEO tenure | less than a year |
| CEO ownership | 0.4% |
| Management average tenure | less than a year |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio
Aug 23Aerie Pharmaceuticals grants 16.9K stock options
Aug 15Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales
Aug 05Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan
Jun 17Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Feb 27
Who Has Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?
Jan 28Aerie Pharmaceuticals receives European approval for Roclanda
Jan 11Aerie Pharmaceuticals (NASDAQ:AERI) Share Prices Have Dropped 76% In The Last Three Years
Dec 24Is Aerie Pharmaceuticals (NASDAQ:AERI) A Risky Investment?
Nov 28
European advisory group backs Aerie Pharma's Roclanda
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$37m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$4m | US$24k | -US$75m |
Compensation vs Market: Raj's total compensation ($USD4.25M) is about average for companies of similar size in the US market ($USD3.95M).
Compensation vs Earnings: Insufficient data to compare Raj's compensation with company performance.
CEO
Raj Kannan (58 yo)
less than a year
Tenure
US$4,253,490
Compensation
Mr. Raj Kannan serves as Chief Executive Officer and Director at Aerie Pharmaceuticals, Inc since December 20, 2021 and serves as its Principal Financial Officer since March 1, 2022. He has been Chief Exec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Principal Financial Officer & Director | less than a year | US$4.25m | 0.44% $ 3.3m | |
| Co-Founder | 17.8yrs | US$1.46m | 0.57% $ 4.3m | |
| General Counsel & Secretary | 4.8yrs | US$1.45m | 0.11% $ 817.1k | |
| Chief Financial Officer | less than a year | no data | 0.18% $ 1.4m | |
| Head of Clinical Development & Operations | no data | no data | no data | |
| VP of Finance & Principal Accounting Officer | 3.4yrs | no data | 0.038% $ 283.4k | |
| Senior Director of Communications | 1.2yrs | no data | no data | |
| Head of Human Resources | less than a year | no data | no data | |
| Head of Regulatory Affairs & Quality Assurance | less than a year | no data | no data | |
| Head of Business Development | less than a year | no data | no data | |
| Head of Manufacturing | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
0.8yrs
Average Tenure
57.5yo
Average Age
Experienced Management: AERI's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Principal Financial Officer & Director | less than a year | US$4.25m | 0.44% $ 3.3m | |
| Independent Chairman | 8.2yrs | US$1.77m | 0.085% $ 640.3k | |
| Independent Director | 4.2yrs | US$168.67k | 0.027% $ 205.7k | |
| Independent Director | 7.4yrs | US$163.67k | 0.033% $ 245.5k | |
| Independent Director | 2.4yrs | US$161.17k | 0.016% $ 121.9k | |
| Independent Director | 7.5yrs | US$169.05k | 0.033% $ 245.5k | |
| Independent Director | 7.4yrs | US$173.67k | 0.033% $ 245.5k |
7.4yrs
Average Tenure
67yo
Average Age
Experienced Board: AERI's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/21 21:52 |
| End of Day Share Price | 2022/11/18 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aerie Pharmaceuticals, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Difei Yang | Brean Capital |
| John Newman | Canaccord Genuity |